THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

(“BiVictriX” or “the Company” or “the Group”)

Full year results for the twelve months ended 31 December 2022

• Good progress towards identifying a clinical candidate
• Broadening and strengthening the Company’s pipeline portfolio
• Expansion of scientific capabilities and premises

Alderley Park, 30 March 2023 – BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies with improved tolerability and anti-cancer activity, today announces its audited full year results for the twelve months ended 31 December 2022.

The Annual Report is available to review on the Company’s website and hard copies will be posted to shareholders shortly.

Corporate Highlights including post period end events

• Identified a development lead for the BVX001 programme which will be progressed to in vivo studies
• Expanded the therapeutic pipeline with two additional programmes, BVX002 and BVX003, both entering the early stages of drug development

• Developed a unique, state-of-the-art, Bi-Cygni® discovery engine that will feed the Company’s growing proprietary Bi-Cygni® library, IP portfolio and expanding therapeutic pipeline
• Expanded the newly established internal R&D premises at Alderley Park, UK, to incorporate a dedicated protein expression division and biomarker discovery unit
• Post period, the Company announced the appointment of Dr. Michael Kauffman as Non-Executive Chairman
• Post period, the Company reported positive preclinical data with the BVX001 programme, demonstrating a highly favourable safety profile compared to MylotargTM in an in vivo model assessing the risk for bone marrow toxicity and neutropenia

Financial highlights

• Increased investment in R&D of £2.1 million (2021: £0.7 million)
• Loss after tax of £2.5 million (2021: £2.3 million)
• Closing cash balance of £3.3 million at 31 December 2022 (2021: £6.1 million)

Tiffany Thorn, Chief Executive Officer of BiVictriX, commented: “We have made significant progress over the past year with our lead programme, BVX001, advancing this candidate towards the clinic. In addition to identifying a development lead for BVX001, at the beginning of this year we reported a highly favourable safety profile in a preclinical study comparing two doses of BVX001 to the only currently approved ADC indicated for AML. Beyond BVX001, we’ve diversified our pipeline with the addition of two additional programmes, BVX002 and BVX003, to our portfolio. Further, we’ve established of our new wholly-owned Bi-Cygni® discovery engine, laying the groundwork for future expansion and value creation in the years ahead.”

For more information, please contact:

BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer                                          Email: info@bivictrix.com

SP Angel Corporate Finance LLP (NOMAD and Broker)     Tel: +44 (0) 20 3470 0470
David Hignell, Kasia Brzozowska (Corporate Finance)
Vadim Alexandre, Rob Rees (Sales and Broking)

Panmure Gordon (UK) Limited (Joint Broker)                        Tel: +44 (0) 20 7886 2500
Rupert Dearden, Freddy Crossley, Emma Earl

Consilium Strategic Communications
Mary-Jane Elliott, Namrata Taak, Genevieve Wilson,           Tel: +44 (0) 20 3709 5700
Emmalee Hoppe                                                                                       Email: bivictrix@consilium-comms.com

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or “Bi-Cygni® fingerprints”, on tumour cells, which are largely absent from healthy cells.

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company’s novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com.

Please Read PDF RNS HERE